Quantification of Residual Tumor Cells in Monoclonal B-cell Lymphoma

  • Thomas Pfitzner
  • Andreas Engert
  • Stefan Barth


With the advent of more effective therapeutic modalities, better methods to evaluate and quantify minimal residual disease (MRD) in patients with malignant lymphoma are needed. These methods should be highly sensitive in detecting very low amounts of malignant cells and should be specific for the malignant clone. In addition, these methods should allow the quantification of residual tumor cells. At present, the highest sensitivity is reached with PCR, allowing the detection of one malignant cell in 106 normal cells [1]. The clone-specific hypervariable complementarity determining regions (CDRs) of the immunoglobulin heavy chain locus (IgVH) provide a useful marker for monitoring MRD in B-cell lymphoma during and after treatment [2, 3].


Minimal Residual Disease Hybridization Probe Immunoglobulin Heavy Chain Complementarity Determine Region Residual Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Roberts W, Estrov Z, Zipf T (1995) Detection of minimal residual disease in acute lymphoblastic leukemia [letter; comment]. Blood 86: 237–9Google Scholar
  2. 2.
    Maloum K, Pritsch O, Dighiero G (1997) Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Hematol Cell Ther 39: 19–24CrossRefGoogle Scholar
  3. 3.
    Schultze JL, Donovan JW, Gribben JG (1999) Minimal residual disease detection after myeloablative chemotherapy in chronic lymphytic leukemia. J Mol Med 77: 259–265PubMedCrossRefGoogle Scholar
  4. 4.
    Zwicky C, Maddocks A, Andersen N, Gribben J (1996) Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin’s lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 88: 3314–22PubMedGoogle Scholar
  5. 5.
    Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor NYGoogle Scholar
  6. 6.
    Kueppers R, Hansmann ML, Rajewsky K (1996) Micromanipulation and PCR analysis of single cells from tissue sections. In: Herzenberg LA, Weir D, Blackwell D (eds) Handbook of Experimental Immunology, 5“ edn., Blackwell Science Ltd., Oxford 206.1–206. 4.Google Scholar
  7. 7.
    Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A (1995) High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85: 596–602Google Scholar
  8. 8.
    Boleda M, Briones P, Farces J, Tyfield L, Pi R (1996) Experimental design: a useful tool for PCR optimization. Biotechniques 211: 34–40Google Scholar
  9. 9.
    Wang Z, Spadoro J (1998) Determination of target copy number of quantitative standards used in PCR-based diagnosticassays. In Ferre F (ed) Gene Quantification. Birkhäuser, Boston 33–43Google Scholar
  10. 10.
    Jeffreys AJ, Wilson V, Neumann R, Keyte J (1988) Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells. Nucleic Acids Res 16: 10953–71PubMedCrossRefGoogle Scholar
  11. 11.
    Pfitzner T, Engert A, Wittor H, Schinköthe T, Oberhäuser F, Schulz H, Diehl V, Barth S (2000): A real-time PCR assay for the quantification of residual malignant cells in B-cell chronic lymphatic leukemia. Leukemia (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Thomas Pfitzner
    • 1
  • Andreas Engert
  • Stefan Barth
  1. 1.Labor für Immuntherapie, LFI, E4, R 703Thomas Pfitzner Medizinische Klinik I der Universitaet zu KölnKölnGermany

Personalised recommendations